Literature DB >> 31202630

Mid- to long-term follow-up of shoulder arthroplasty for primary glenohumeral osteoarthritis in patients aged 60 or under.

Lionel Neyton1, Jacob M Kirsch2, Philippe Collotte1, Philippe Collin3, Louis Gossing1, Mikael Chelli1, Gilles Walch1.   

Abstract

BACKGROUND: Shoulder arthroplasty in young patients with primary glenohumeral osteoarthritis is an area of continued controversy.
METHODS: A retrospective multicenter study was performed for all patients aged 60 years or less undergoing either hemiarthroplasty (HA) or total shoulder arthroplasty (TSA) for primary glenohumeral osteoarthritis with a minimum of 24-month follow-up. Clinical and functional outcomes, complications, and need for revision surgery were analyzed. Survivorship analysis using revision arthroplasty as an endpoint was determined.
RESULTS: A total of 202 patients with a mean age of 55.3 years (range, 36-60 years) underwent TSA with a mean follow-up of 9 years (range, 2-24.7 years). Revision arthroplasty was performed in 33 (16.3%) shoulders, with glenoid failure associated with the revision in 29 shoulders (88%). TSA survivorship analysis demonstrated 95% free of revision at 5 years, 83% at 10 years, and 60% at 20-year follow-up. A total of 31 patients with a mean age of 52.5 years (range, 38-60 years) underwent HA with a mean follow-up of 8.7 years (range, 2-21.4 years). Revision arthroplasty was performed in 5 (16.1%) shoulders, with glenoid erosion as the cause for revision in 4 shoulders (80%). HA survivorship analysis demonstrated 84% free from revision at 5 years and 79% at the final follow-up. TSA resulted in a significantly better range of motion, pain, subjective shoulder value, and Constant score compared with HA.
CONCLUSION: In young patients with primary glenohumeral osteoarthritis, TSA resulted in significantly better functional and subjective outcomes with no significant difference in longitudinal survivorship compared with patients treated with HA.
Copyright © 2019 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Shoulder arthroplasty; glenohumeral arthritis; hemiarthroplasty; primary arthritis; total shoulder arthroplasty

Mesh:

Year:  2019        PMID: 31202630     DOI: 10.1016/j.jse.2019.03.006

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  6 in total

Review 1.  Shoulder Arthroplasty Options for Glenohumeral Osteoarthritis in Young and Active Patients (<60 Years Old): A Systematic Review.

Authors:  Hélder Fonte; Tiago Amorim-Barbosa; Sara Diniz; Luís Barros; Joaquim Ramos; Rui Claro
Journal:  J Shoulder Elb Arthroplast       Date:  2022-03-23

2.  Arthroscopic management of glenohumeral arthritis in the young patient does not negatively impact the outcome of subsequent anatomic shoulder arthroplasty.

Authors:  Corey J Schiffman; Anastasia J Whitson; Sagar S Chawla; Frederick A Matsen; Jason E Hsu
Journal:  Int Orthop       Date:  2021-07-13       Impact factor: 3.075

3.  Revision of a Stemless Anatomic Implant into a Stemless Reverse Implant.

Authors:  Christian Schoch; Michael Dittrich; Leander Ambros; Michael Geyer
Journal:  Case Rep Orthop       Date:  2021-01-11

4.  Resurfacing hemiarthroplasty versus stemmed hemiarthroplasty for glenohumeral osteoarthritis: a meta-analysis.

Authors:  Baoliang Zhang; Guanghui Chen; Tianqi Fan; Zhongqiang Chen
Journal:  Arthroplasty       Date:  2020-09-01

5.  Clinical and radiographic outcomes of reverse shoulder arthroplasty using a hybrid baseplate fixation mechanism.

Authors:  Lionel Neyton; Ana Nigues; Floris Van Rooij; Sheng Zhang; Philippe Collin
Journal:  JSES Int       Date:  2021-09-04

6.  Midterm results of pyrocarbon interposition shoulder arthroplasty: good outcomes after posttraumatic osteonecrosis without malunion of the tuberosities.

Authors:  Jérôme Garret; Arnaud Godenèche; Pascal Boileau; Daniel Molé; Mikael Etzner; Luc Favard; Christophe Lévigne; François Sirveaux; Gilles Walch
Journal:  JSES Int       Date:  2022-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.